Kaliszewski Krzysztof, Diakowska Dorota, Strutynska-Karpinska Marta, Rzeszutko Marta, Grzegrzolka Jedrzej, Dziegiel Piotr, Wojtczak Beata, Sutkowski Krzysztof
1st Department and Clinic of General, Gastroenterological, and Endocrine Surgery, Wroclaw Medical University, Wroclaw, Poland.
Folia Histochem Cytobiol. 2016;54(4):193-201. doi: 10.5603/FHC.a2016.0025. Epub 2017 Jan 4.
Cytokeratin-19 (CK19) is recognized as a reliable tumor marker of papillary thyroid carcinoma (PTC). The general prognosis in the classical subtype of PTC (CSTPTC) remains favorable, but some cases can be very aggressive. The aim of this study was to evaluate the localization and intensity of immunohistochemical CK19 expression in CSTPTC and its associations with the clinical and pathological characteristics of patients with CSTPTC in the Silesian region.
All the available clinical and histopathological data for 149 patients with CSTPTC from the Silesian region were retrospectively analyzed. The group consisted of 135 (90.6%) women and 14 (9.4%) men (mean age and SD: 52.3 ± 15.0). All these patients with CSTPTC underwent surgery at the same center between 2008 and 2013; the follow-up period was 24 to 90 months (mean and SD: 47 ± 20).
In 142 (95.3%) of the patients with CSTPTC, positive cytoplasmic staining of CK19 was found. A higher expression of CK19 was observed in the group of patients without the recurrence of the disease (p = 0.015). CK19 expression was not associated with age, gender, tumor focality, disease stage, tumor size (pT), lymph node involvement (pN), or distant metastases (pM).
Decreased CK19 expression in CSTPTC cases with relapse suggests that it plays a role in the carcinoma progression of CSTPTC. The association between lower CK19 expression and patients' unfavorable postoperative course could suggest its possible role as a marker of CSTPTC poor prognosis.
细胞角蛋白19（CK19）被认为是甲状腺乳头状癌（PTC）可靠的肿瘤标志物。PTC经典亚型（CSTPTC）的总体预后仍然良好，但有些病例可能具有很强的侵袭性。本研究的目的是评估CSTPTC中免疫组化CK19表达的定位和强度及其与西里西亚地区CSTPTC患者临床和病理特征的相关性。
回顾性分析了西里西亚地区149例CSTPTC患者所有可用的临床和组织病理学数据。该组包括135名（90.6%）女性和14名（9.4%）男性（平均年龄和标准差：52.3±15.0）。所有这些CSTPTC患者于2008年至2013年在同一中心接受手术；随访期为24至90个月（平均和标准差：47±20）。
在142例（95.3%）CSTPTC患者中发现CK19胞质染色呈阳性。在无疾病复发的患者组中观察到CK19表达较高（p = 0.015）。CK19表达与年龄、性别、肿瘤灶性、疾病分期、肿瘤大小（pT）、淋巴结受累（pN）或远处转移（pM）无关。
复发的CSTPTC病例中CK19表达降低表明其在CSTPTC的癌进展中起作用。较低的CK19表达与患者术后不良病程之间的关联可能表明其作为CSTPTC预后不良标志物的潜在作用。
